Learn More
e13065 Background: Crizotinib is a selective, ATP-competitive, small molecule inhibitor of the ALK and MET/HGF receptor tyrosine kinases. Crizotinib is currently being developed as an orally administered agent in treatment of advanced ALK-positive NSCLC. The recommended clinical dose is 250 mg BID. METHODS Plasma crizotinib concentration data were(More)
Prediction of subsequent risks of breast carcinoma (BC) development in intraductal papilloma (IDP) has remained controversial with the exception of atypical papilloma (AP). The potential value of immunohistochemistry (IHC) of cytokeratin 5/6 [CK5/6] and p63 have been proposed but its standardization has also remained controversial. We studied 17 patients(More)
  • 1